Suppr超能文献

九种粪便免疫化学检测用于结直肠癌检测的比较评估。

Comparative evaluation of nine faecal immunochemical tests for the detection of colorectal cancer.

机构信息

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center , Germany.

出版信息

Acta Oncol. 2013 Nov;52(8):1667-75. doi: 10.3109/0284186X.2013.789141. Epub 2013 Apr 25.

Abstract

BACKGROUND

Faecal immunochemical tests (FITs) for haemoglobin are increasingly used for non-invasive screening for colorectal cancer (CRC) but large scale comparative studies of different FITs for detection of CRC, overall and by stage, are sparse. We aimed to determine and compare performance of different FITs for the detection of CRC, and to assess their stage-specific sensitivities.

MATERIAL AND METHODS

We assessed sensitivity, specificity and their corresponding 95% confidence intervals for six qualitative FITs among 74 CRC cases (59% stage I or II cancers) and 1480 controls free of colorectal neoplasm. Overall and stage-specific receiver operating characteristic curves were derived for three quantitative FITs. The areas under the curves (AUCs) were calculated and compared.

RESULTS

Pairs of overall sensitivity and specificity of the qualitative FITs ranged from 66% and 96% to 92% and 62%, respectively. For the three quantitative tests, AUCs ranged from 0.90 to 0.92, with sensitivities ranging from 80% to 87% at cut-offs yielding 90% specificity. AUCs ranged from 0.85 to 0.92, 0.94 to 0.96, and 0.86 to 0.93 for stage I, stage II and advanced stages (stage III and IV) cancers, respectively. At a specificity of 90%, the tests detected 65%-85% of stage I cancers.

CONCLUSION

The diagnostic performance of FITs regarding detection of CRC is promising, even though the pre-defined cut-offs of some of the qualitative FITs need to be adjusted to limit false-positive rates in screening setting. At cut-off levels yielding 90% specificity, the quantitative tests detected the vast majority of CRCs, even at early stages.

摘要

背景

粪便免疫化学检测(FIT)用于血红蛋白检测,逐渐成为结直肠癌(CRC)非侵入性筛查的手段,但关于不同 FIT 检测 CRC 的大规模对比研究较少,包括整体和各期 CRC 的情况。我们旨在确定并比较不同 FIT 检测 CRC 的性能,并评估其各期 CRC 的特异性敏感性。

材料和方法

我们评估了 6 种定性 FIT 在 74 例 CRC 病例(59%为 I 期或 II 期癌症)和 1480 例无结直肠肿瘤对照中的敏感性、特异性及其相应的 95%置信区间。为 3 种定量 FIT 绘制了总体和各期特异性的受试者工作特征曲线,并计算和比较了曲线下面积(AUC)。

结果

定性 FIT 的总体敏感性和特异性的配对范围分别为 66%和 96%至 92%和 62%。对于三种定量检测,AUC 范围从 0.90 到 0.92,在特异性为 90%的情况下,截止值为 80%到 87%,灵敏度范围为 80%到 87%。AUC 范围为 0.85 到 0.92、0.94 到 0.96 和 0.86 到 0.93,分别用于 I 期、II 期和晚期(III 期和 IV 期)癌症。在特异性为 90%的情况下,这些检测可检出 65%-85%的 I 期癌症。

结论

即使一些定性 FIT 的预定义截止值需要调整以限制筛查中的假阳性率,FIT 检测 CRC 的诊断性能仍有前景。在特异性为 90%的情况下,定量检测可检测到绝大多数 CRC,即使是早期阶段。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验